ALNA News and Press, Allena Pharmaceuticals Inc. From 06/04/19

-- Substantial Treatment Effect Observed in Patients with Enteric Hyperoxaluria, Including Robust Reductions in Both Urine and Plasma Oxalate – -- Reloxaliase Well-Tolerated Over 12 Weeks of Dosing -- -- Detailed Results to be Presented at OHF International Hyperoxaluria Worksho...

NEWTON, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, to...

Gainers:  Soliton (NASDAQ: SOLY ) +124% . Exela Technologies (NASDAQ: XELA ) +33% . Flexible Solutions International (NYSEMKT: FSI ) +24% . IMAC Holdings (NASDAQ: IMAC ) +20% . Biocept (NASDAQ: BIOC ) +21% . Anaplan (NYSE: PLAN ) +18% . MYnd Analytics (NASDAQ: MYND ) +18% . Sea...

Allena Pharmaceuticals (NASDAQ: ALNA ): Q1 GAAP EPS of -$0.55  misses by $0.06 . More news on: Allena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

-- Entered into Agreement with Duke Clinical Research Institute (DCRI) to Support Phase 3 URIROX-2™ Trial and Promote Enteric Hyperoxaluria Disease Awareness – -- All Clinical Programs Progressing on Track; Expect to Report Initial Data from Study 206 in Second Quarter a...

NEWTON, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...

Allena Pharmaceuticals ( ALNA ) is a micro-cap targeting a very specific niche indication called Hyperoxaluria, a metabolic disorder characterized by significantly elevated oxalate levels in the urine. Its entire pipeline is centered around various forms of this disease. Its lead drug candidat...

NEWTON, Mass., March 27, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...

The following slide deck was published by Allena Pharmaceuticals, Inc. in conjunction with this Read more ...

Allena Pharmaceuticals (NASDAQ: ALNA ): Q4 GAAP EPS of -$0.46. More news on: Allena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...